Indoleamine 2,3-Dioxygenase and tolerance: Where Are We Now?

Andrew L. Mellor, Henrique Lemos, Lei Huang

Research output: Contribution to journalShort survey

33 Citations (Scopus)

Abstract

Cells expressing IDO suppress innate and adaptive immunity to promote tolerance by catabolizing the amino acid tryptophan (Trp) and other indole compounds. Interferon type I (IFN-I) and type II (IFN-II) produced at sites of inflammation or by activated immune cells are potent IDO inducers because mammalian IDO genes contain IFN response elements. Elevated IDO expression by dendritic cells (DCs) is of particular significance because IDO activity converts mature DCs into tolerogenic APCs that suppress effector T cells (Teff) and promote regulatory T cells (Tregs), thereby promoting tolerance. Local Trp depletion and production of immune suppressive Trp catabolites contribute to tolerogenic processes by activating metabolic pathways responsive to amino acid withdrawal and aryl hydrocarbon signaling, respectively. Sustained IDO elevation creates local immune privilege that protects tissues from immune-mediated damage and allows tissues to heal. This response occurs in lymphoid tissues when DNA released by dying tissue cells is sensed to induce specialized DC subsets to acquire tolerogenic phenotypes. The tolerogenic effects of IDO also promote tumorigenesis and help establish immune checkpoints in cancer, as malignant cells are protected from immune surveillance. Similar processes may attenuate host immunity to some pathogens that persist in immunocompetent individuals. However, if inflammation with IDO involvement is not resolved, chronic immune activation at such sites causes progressive tissue damage over time. Another effect of sustained IDO activity is enhanced pain sensitivity, as some Trp catabolites produced by cells expressing IDO are neuroactive. In this review, we summarize links between IDO and chronic inflammatory diseases and discuss prospects for exploiting IDO and Trp catabolism to suppress immunity and promote tolerance for clinical benefit, with particular emphasis on protecting tissues from destructive autoimmunity.

Original languageEnglish (US)
Article number1360
JournalFrontiers in immunology
Volume8
Issue numberOCT
DOIs
StatePublished - Oct 27 2017

Fingerprint

Indoleamine-Pyrrole 2,3,-Dioxygenase
Tryptophan
Dendritic Cells
Immunity
Eragrostis
Inflammation
Amino Acids
Interferon Type I
Response Elements
Adaptive Immunity
Lymphoid Tissue
Regulatory T-Lymphocytes
Hydrocarbons
Metabolic Networks and Pathways
Autoimmunity
Innate Immunity
Carcinogenesis
Chronic Disease
T-Lymphocytes
Phenotype

Keywords

  • Autoimmunity
  • Indoleamine 2,3-dioxygenase
  • Nociceptive pain
  • Tolerance
  • Transplant
  • Transplantation immunology

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Cite this

Indoleamine 2,3-Dioxygenase and tolerance : Where Are We Now? / Mellor, Andrew L.; Lemos, Henrique; Huang, Lei.

In: Frontiers in immunology, Vol. 8, No. OCT, 1360, 27.10.2017.

Research output: Contribution to journalShort survey

Mellor, Andrew L. ; Lemos, Henrique ; Huang, Lei. / Indoleamine 2,3-Dioxygenase and tolerance : Where Are We Now?. In: Frontiers in immunology. 2017 ; Vol. 8, No. OCT.
@article{c4ec1a7a81e941e5ad8b3f7dd30e4ae5,
title = "Indoleamine 2,3-Dioxygenase and tolerance: Where Are We Now?",
abstract = "Cells expressing IDO suppress innate and adaptive immunity to promote tolerance by catabolizing the amino acid tryptophan (Trp) and other indole compounds. Interferon type I (IFN-I) and type II (IFN-II) produced at sites of inflammation or by activated immune cells are potent IDO inducers because mammalian IDO genes contain IFN response elements. Elevated IDO expression by dendritic cells (DCs) is of particular significance because IDO activity converts mature DCs into tolerogenic APCs that suppress effector T cells (Teff) and promote regulatory T cells (Tregs), thereby promoting tolerance. Local Trp depletion and production of immune suppressive Trp catabolites contribute to tolerogenic processes by activating metabolic pathways responsive to amino acid withdrawal and aryl hydrocarbon signaling, respectively. Sustained IDO elevation creates local immune privilege that protects tissues from immune-mediated damage and allows tissues to heal. This response occurs in lymphoid tissues when DNA released by dying tissue cells is sensed to induce specialized DC subsets to acquire tolerogenic phenotypes. The tolerogenic effects of IDO also promote tumorigenesis and help establish immune checkpoints in cancer, as malignant cells are protected from immune surveillance. Similar processes may attenuate host immunity to some pathogens that persist in immunocompetent individuals. However, if inflammation with IDO involvement is not resolved, chronic immune activation at such sites causes progressive tissue damage over time. Another effect of sustained IDO activity is enhanced pain sensitivity, as some Trp catabolites produced by cells expressing IDO are neuroactive. In this review, we summarize links between IDO and chronic inflammatory diseases and discuss prospects for exploiting IDO and Trp catabolism to suppress immunity and promote tolerance for clinical benefit, with particular emphasis on protecting tissues from destructive autoimmunity.",
keywords = "Autoimmunity, Indoleamine 2,3-dioxygenase, Nociceptive pain, Tolerance, Transplant, Transplantation immunology",
author = "Mellor, {Andrew L.} and Henrique Lemos and Lei Huang",
year = "2017",
month = "10",
day = "27",
doi = "10.3389/fimmu.2017.01360",
language = "English (US)",
volume = "8",
journal = "Frontiers in Immunology",
issn = "1664-3224",
publisher = "Frontiers Media S. A.",
number = "OCT",

}

TY - JOUR

T1 - Indoleamine 2,3-Dioxygenase and tolerance

T2 - Where Are We Now?

AU - Mellor, Andrew L.

AU - Lemos, Henrique

AU - Huang, Lei

PY - 2017/10/27

Y1 - 2017/10/27

N2 - Cells expressing IDO suppress innate and adaptive immunity to promote tolerance by catabolizing the amino acid tryptophan (Trp) and other indole compounds. Interferon type I (IFN-I) and type II (IFN-II) produced at sites of inflammation or by activated immune cells are potent IDO inducers because mammalian IDO genes contain IFN response elements. Elevated IDO expression by dendritic cells (DCs) is of particular significance because IDO activity converts mature DCs into tolerogenic APCs that suppress effector T cells (Teff) and promote regulatory T cells (Tregs), thereby promoting tolerance. Local Trp depletion and production of immune suppressive Trp catabolites contribute to tolerogenic processes by activating metabolic pathways responsive to amino acid withdrawal and aryl hydrocarbon signaling, respectively. Sustained IDO elevation creates local immune privilege that protects tissues from immune-mediated damage and allows tissues to heal. This response occurs in lymphoid tissues when DNA released by dying tissue cells is sensed to induce specialized DC subsets to acquire tolerogenic phenotypes. The tolerogenic effects of IDO also promote tumorigenesis and help establish immune checkpoints in cancer, as malignant cells are protected from immune surveillance. Similar processes may attenuate host immunity to some pathogens that persist in immunocompetent individuals. However, if inflammation with IDO involvement is not resolved, chronic immune activation at such sites causes progressive tissue damage over time. Another effect of sustained IDO activity is enhanced pain sensitivity, as some Trp catabolites produced by cells expressing IDO are neuroactive. In this review, we summarize links between IDO and chronic inflammatory diseases and discuss prospects for exploiting IDO and Trp catabolism to suppress immunity and promote tolerance for clinical benefit, with particular emphasis on protecting tissues from destructive autoimmunity.

AB - Cells expressing IDO suppress innate and adaptive immunity to promote tolerance by catabolizing the amino acid tryptophan (Trp) and other indole compounds. Interferon type I (IFN-I) and type II (IFN-II) produced at sites of inflammation or by activated immune cells are potent IDO inducers because mammalian IDO genes contain IFN response elements. Elevated IDO expression by dendritic cells (DCs) is of particular significance because IDO activity converts mature DCs into tolerogenic APCs that suppress effector T cells (Teff) and promote regulatory T cells (Tregs), thereby promoting tolerance. Local Trp depletion and production of immune suppressive Trp catabolites contribute to tolerogenic processes by activating metabolic pathways responsive to amino acid withdrawal and aryl hydrocarbon signaling, respectively. Sustained IDO elevation creates local immune privilege that protects tissues from immune-mediated damage and allows tissues to heal. This response occurs in lymphoid tissues when DNA released by dying tissue cells is sensed to induce specialized DC subsets to acquire tolerogenic phenotypes. The tolerogenic effects of IDO also promote tumorigenesis and help establish immune checkpoints in cancer, as malignant cells are protected from immune surveillance. Similar processes may attenuate host immunity to some pathogens that persist in immunocompetent individuals. However, if inflammation with IDO involvement is not resolved, chronic immune activation at such sites causes progressive tissue damage over time. Another effect of sustained IDO activity is enhanced pain sensitivity, as some Trp catabolites produced by cells expressing IDO are neuroactive. In this review, we summarize links between IDO and chronic inflammatory diseases and discuss prospects for exploiting IDO and Trp catabolism to suppress immunity and promote tolerance for clinical benefit, with particular emphasis on protecting tissues from destructive autoimmunity.

KW - Autoimmunity

KW - Indoleamine 2,3-dioxygenase

KW - Nociceptive pain

KW - Tolerance

KW - Transplant

KW - Transplantation immunology

UR - http://www.scopus.com/inward/record.url?scp=85032224500&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85032224500&partnerID=8YFLogxK

U2 - 10.3389/fimmu.2017.01360

DO - 10.3389/fimmu.2017.01360

M3 - Short survey

AN - SCOPUS:85032224500

VL - 8

JO - Frontiers in Immunology

JF - Frontiers in Immunology

SN - 1664-3224

IS - OCT

M1 - 1360

ER -